AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 42 min read$INSP

Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance?

Inspire Medical Systems (INSP) reported Q2 2026 adjusted EPS of $0.14, beating estimates, and raised its 2026 revenue and earnings guidance. Despite U.S. coding and reimbursement challenges, international revenues supported the revised outlook. The stock has seen volatility, with a 50.86% 90-day return but a 32.65% YTD decline. Analysts' price targets range from $40 to $85, with a consensus of $60.40, suggesting a 3% overvaluation.

Original reporting
simplywall.st
Published Sep 4, 2026, 5:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 2:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance? — source image
Source · simplywall.st
Decision brief

The 30-second read

$INSPBullishMed
01

Why it matters

The earnings beat and guidance raise short‑term sentiment but long‑term risk remains due to reimbursement issues.

02

Market read

Earnings surprise and guidance update are the primary drivers of relevance for this small‑cap health‑tech stock.

03

What to watch

International revenue contribution and potential future regulatory changes.

Relevance 7/10Novelty 7/10Timing: post‑quarter earnings release

Background

Simply Wall St provides a valuation narrative and price target range for Inspire Medical Systems.

Company-level read

Ticker impact

$INSPBullishMedium confidence
Context

Q2 2026 adjusted EPS of $0.14 beat expectations and management raised 2026 revenue and earnings guidance.

Expected impact

Potential modest price rally on the news, but volatility likely persists.

Evidence & confidence

Guidance lift is new information, yet the company faces coding/reimbursement risks that cap upside.

Market effects

Sector

Highlights ongoing reimbursement challenges for med‑tech firms, may affect peer valuations.

Regional

U.S. med‑tech sector sentiment could see slight lift.

Global

Limited to investors tracking small‑cap healthcare equities.

Counterpoint

What could challenge this read

Higher guidance may be overly optimistic given persistent coding uncertainties.

Key entities

  • company
    Inspire Medical Systems

    Medical device maker reporting Q2 2026 results.

Read at source← All news

Related articles

SEP 11
$INSPHigh

Why Inspire Medical Systems (INSP) Stock Is Up Today

Inspire Medical Systems (INSP) stock rose 7.4% after Stifel raised its price target to $80.00, citing positive sentiment. Shares later cooled to $70.71, up 3.8%. The company's shares are volatile, with significant moves tied to regulatory changes and analyst upgrades. INSP is down 23.4% YTD and 50.9% off its 52-week high.

financialcontent.com2 min
AUG 14
$INSPMedAI 8/10

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems (NYSE:INSP) reported Q2 2026 revenue of $200.6M, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Gross margin rose to 85.5%. Full-year revenue guidance was raised to $835M-$875M, with an estimated $40M Q2 and $120M-$130M full-year reimbursement headwind.

aol.com7 min
AUG 11
$INSPMedAI 8/10

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems (INSP) reported Q2 2026 revenue of $200.6 million, down 7.6% year over year, citing coding and reimbursement disruptions. Adjusted diluted EPS was $0.14 versus $0.34 a year earlier. Management raised full-year revenue guidance to $835 million to $875 million and estimated a $40 million Q2 adverse impact, with $120 million to $130 million for the year.

fool.com7 min
AUG 10
$INSPMedAI 8/10

5 Insightful Analyst Questions From Inspire Medical Systems’s Q2 Earnings Call

Inspire Medical Systems (INSP) reported Q2 results with improved coding clarity and cost discipline, citing outperformance versus Wall Street expectations despite year-on-year revenue decline. Revenue was $200.6M vs $194.7M estimate, adjusted EPS $0.14 vs -$0.25, and adjusted EBITDA $38.9M vs $27.68M. Full-year revenue guidance was raised to $855M and adjusted EPS to $1.25 at the midpoint.

financialcontent.com6 min
AUG 4
$INSPHighAI 9/10

Why Are Inspire Medical Systems (INSP) Shares Soaring Today

Inspire Medical Systems (INSP) shares rose 18.3% after the company reported a “beat and raise” quarter and announced a restructuring initiative. Revenue was $200.6M vs $194.7M consensus, adjusted EPS was $0.14 vs a $0.25 loss expected, and adjusted EBITDA was $38.9M. Full-year revenue guidance midpoint rose to $855M and adjusted EPS to $1.25. Oppenheimer upgraded to Outperform with an $85 target.

financialcontent.com4 min